GRI Bio
5 hedge funds and large institutions have $177K invested in GRI Bio in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 3 closing their positions.
114% more capital invested
Capital invested by funds: $82.8K → $177K (+$94.4K)
48.06% more ownership
Funds ownership: 7.34% → 55.4% (+48%)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
25% more funds holding
Funds holding: 4 → 5 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$256K |
| 2 |
HF
HRT Financial
New York
|
+$17.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$17.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.53K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$8.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$33K |
| 2 |
Renaissance Technologies
New York
|
-$15K |
| 3 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
-$9.62K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.14K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$5.66K |
GRI Hedge Fund Activity: Q1 2024 in Review
5 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in GRI Bio (GRI) for Q1 2024, worth a combined $177K — up 114% from $82.8K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GRI positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $256K. The largest seller was Citadel Advisors, exiting entirely with an estimated $33K sold.
- 5 institutional investors held GRI Bio (GRI) as of Q1 2024, up from 4 in Q4 2023.
- Funds reported $177K of GRI Bio stock for Q1 2024, up 114% quarter-over-quarter.
- 4 funds opened new GRI Bio positions in Q1 2024 and 3 closed out, a net change of +1 holder.
- The largest GRI Bio buyer in Q1 2024 was Altium Capital Management, an estimated $256K added.
- The largest GRI Bio seller in Q1 2024 was Citadel Advisors, an estimated $33K sold.
Based on aggregated 13F filings for Q1 2024.